Advertisement

Context Therapeutics Inc. CNTX

Set alert

Price alert · CNTX

All alert types
0.19 USD -0.01 -6.25%

At close · Oct 30

0.19 0.00 +1.96%

After hours · Oct 30, 4:00 PM ET

Bid
0.19 × 3
Ask
0.19 × 3
0.1888 Day range 0.203
0.1888 52-week range 3.62
YTD
-87.14%
1 year
-83.27%
Open
0.203
Prev close
0.2017
Mkt cap
17.37M
Vol
1.01M
Avg vol
1.53M
EPS
-0.48
P/E
0.00
Div yield
0.00%
More statistics
Low
0.1888
High
0.203
Forward P/E
-3.38
Beta
2.25
Short ratio
2.79
Inst. own
76.40%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
1.79
200-d avg
1.86
1y target
7.70

2Y chart

Chart tools
Interval

Events in this range
  • Nov 6, 2024Earnings: -0.22; estimate -0.11; surprise -100%
  • Nov 25, 2024Rating: D. Boral Capital · — → Buy
Signals (79)
NameDateAgo
MACD: Sell SignalOct 29, 20263 days ago
MACD: Buy SignalOct 26, 20266 days ago
MACD: Sell SignalOct 14, 20262 weeks ago
RSI: OversoldOct 13, 20262 weeks ago
RSI: OversoldSep 29, 20261 month ago
RSI: OversoldSep 11, 20261 month ago
MACD: Buy SignalSep 4, 20261 month ago
MACD: Sell SignalSep 1, 20262 months ago
RSI: OversoldSep 1, 20262 months ago
RSI: OversoldAug 28, 20262 months ago
RSI: OversoldJul 17, 20263 months ago
MACD: Buy SignalJul 1, 20264 months ago
RSI: OversoldJun 9, 20264 months ago
SMA: BearishJun 5, 20264 months ago
MACD: Sell SignalJun 3, 20265 months ago
SMA: BearishJun 2, 20265 months ago
SMA: BullishMay 22, 20265 months ago
MACD: Buy SignalMay 21, 20265 months ago
MACD: Sell SignalMay 15, 20265 months ago
MACD: Buy SignalMay 5, 20266 months ago
SMA: BearishApr 9, 20266 months ago
SMA: BullishMar 31, 20267 months ago
SMA: BearishMar 30, 20267 months ago
MACD: Sell SignalMar 19, 20267 months ago
RSI: OverboughtMar 13, 20267 months ago
RSI: OverboughtMar 11, 20267 months ago
MACD: Buy SignalMar 5, 20268 months ago
RSI: OverboughtMar 5, 20268 months ago
MACD: Sell SignalFeb 9, 20268 months ago
RSI: OverboughtJan 23, 20269 months ago
MACD: Buy SignalJan 22, 20269 months ago
MACD: Sell SignalJan 16, 20269 months ago
RSI: OverboughtDec 31, 202510 months ago
SMA: BullishDec 29, 202510 months ago
SMA: BearishDec 23, 202510 months ago
SMA: BullishDec 19, 202510 months ago
MACD: Buy SignalDec 15, 202510 months ago
SMA: BearishNov 25, 202511 months ago
SMA: BullishNov 24, 202511 months ago
SMA: BearishNov 21, 202511 months ago
SMA: BullishNov 19, 202511 months ago
SMA: BearishNov 18, 202511 months ago
MACD: Sell SignalOct 22, 20251 year ago
RSI: OverboughtOct 17, 20251 year ago
RSI: OverboughtOct 9, 20251 year ago
RSI: OverboughtOct 3, 20251 year ago
MACD: Buy SignalSep 18, 20251 year ago
RSI: OverboughtSep 18, 20251 year ago
SMA: BullishSep 17, 20251 year ago
MACD: Sell SignalSep 3, 20251 year ago
MACD: Buy SignalAug 18, 20251 year ago
SMA: BullishAug 13, 20251 year ago
SMA: BearishAug 11, 20251 year ago
SMA: BullishAug 5, 20251 year ago
SMA: BearishAug 4, 20251 year ago
MACD: Sell SignalJul 31, 20251 year ago
RSI: OverboughtJul 16, 20251 year ago
SMA: BullishJul 14, 20251 year ago
MACD: Buy SignalJun 25, 20251 year ago
MACD: Sell SignalJun 20, 20251 year ago
MACD: Buy SignalJun 9, 20251 year ago
RSI: OversoldMay 30, 20251 year ago
SMA: BearishMay 15, 20251 year ago
SMA: BullishMay 13, 20251 year ago
SMA: BearishMay 7, 20251 year ago
MACD: Sell SignalMay 5, 20251 year ago
SMA: BullishApr 11, 20251 year ago
MACD: Buy SignalApr 10, 20251 year ago
MACD: Sell SignalMar 28, 20251 year ago
SMA: BearishMar 26, 20251 year ago
SMA: BullishMar 25, 20251 year ago
MACD: Buy SignalMar 17, 20251 year ago
MACD: Sell SignalMar 12, 20251 year ago
RSI: OversoldJan 28, 20251 year ago
RSI: OversoldDec 27, 20241 year ago
MACD: Buy SignalDec 26, 20241 year ago
MACD: Sell SignalDec 20, 20241 year ago
RSI: OversoldDec 12, 20241 year ago
RSI: OversoldDec 3, 20241 year ago

Key statistics

Market cap
73.50M
Enterprise value
64.96M
Trailing P/E
0.00
Forward P/E
-3.38
PEG ratio
0.00
Price / sales
0.00
Price / book
1.32
EPS (TTM)
-0.88
Beta
2.25
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-12.33M
Total cash
101.54M
Total debt
0
Return on equity
-29.68%
Shares outstanding
75.00M
Short % of float
1.54%
50-day average
1.79
200-day average
1.86

Analyst view

Consensus: none

Price target (mean) 7.70 +3971.9% upside
Target (low)
4.50
Target (mean)
7.70
Target (high)
10.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 7, 2024

Expected Aug 7, 2024. Consensus EPS estimate -0.05.

Earnings history

Financials — quick view

All financials
CNTX Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CNTX Net income — quarterly -14.56M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CNTX EPS — quarterly -0.15
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CNTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.11-0.22-0.11-100.00%
Aug 7, 2024Jun 1, 2024-0.08———
Aug 7, 2024Jun 1, 2024-0.08-0.04+0.04+50.00%
May 8, 2024Mar 1, 2024-0.38-0.23+0.15+39.47%
May 8, 2024Mar 1, 2024-0.38———
Mar 21, 2024Dec 1, 2023-0.35———

Upgrades / downgrades

CNTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 25, 2024D. Boral Capitalinit—Buy
Sep 23, 2024HC Wainwright & Co.reitBuyBuy
Sep 16, 2024HC Wainwright & Co.reitBuyBuy
Jul 10, 2024HC Wainwright & Co.reitBuyBuy
May 16, 2024Piper Sandlerinit—Overweight
May 9, 2024HC Wainwright & Co.mainBuyBuy

About Context Therapeutics Inc.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CNTX — it syncs with the Stock Master app.

Insider holders

CNTX insider holders
InsiderRelationLatest transactionDateShares held
LEHR MARTIN AChief Executive OfficerPurchaseFeb 20, 2023979,891

Institution ownership

CNTX institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp9.89%7,419,3557.27MSep 29, 2024
Nextech Invest Ag9.89%7,419,3557.27MSep 29, 2024
Avidity Partners Management, LP9.89%7,417,1557.27MSep 29, 2024
Great Point Partners LLC9.25%6,934,9826.80MSep 29, 2024
Blue Owl Capital Holdings LP7.22%5,411,2905.30MSep 29, 2024
Vanguard Group Inc4.99%3,744,9613.67MSep 29, 2024

Fund ownership

CNTX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund4.17%3,124,4003.06MSep 29, 2024
Vanguard Extended Market Index Fund0.74%554,824543.73KSep 29, 2024
Fidelity Extended Market Index Fund0.39%295,078289.18KOct 30, 2024
Fidelity Total Market Index Fund0.13%99,06197.08KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%69,66568.27KOct 30, 2024
Vanguard Institutional Index-Inst Total Stock Market Ind0.07%53,12552.06KSep 29, 2024
Advertisement